Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL205894 | 1.00 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL317040 | 1.00 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL630719 | 0.96 | MEN1 (0.46) | MEN1KMT2ANPSR1 | |
| SCHEMBL630773 | 0.92 | MEN1 (0.49) | MEN1KMT2ANPSR1 | |
| SCHEMBL7245273 | 0.92 | MEN1 (0.49) | MEN1KMT2ANPSR1 | |
| SCHEMBL205419 | 0.90 | ALDH1A1 (0.45) | — | |
| SCHEMBL205549 | 0.88 | — | — | |
| SCHEMBL10039818 | 0.88 | — | — | |
| SCHEMBL30578076 | 0.88 | — | — | |
| SCHEMBL8217889 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200172514-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | APOTEX INC. (CA) | 2020-06-04 | — | — | US | disclosed |
| US-10556887-B2 | Processes for the preparation of Veliparib and intermediates thereof | APOTEX INC. (CA) | 2020-02-11 | — | — | US | disclosed |
| US-20190119257-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | THE BANK OF NOVA SCOTIA (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | ABBVIE INC. (US) | 2014-07-31 | — | — | US | disclosed |
| EP-2420499-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-2420234-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION AS PARP INHIBITORS FOR USE IN TREATING CANCER | ABBOTT LAB (US) | 2013-07-10 | — | — | EP | disclosed |
| EP-1869011-B1 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LAB (US) | 2012-08-01 | — | — | EP | disclosed |
| EP-2420234-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as PARP inhibitors for use in treating cancer | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2420499-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position as potent PARP inhibitors | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2012019430-A1 | PHTHALAZINONE DERIVATIVE, AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 上海恒瑞医药有限公司 (CN) | 2012-02-16 | — | — | WO | disclosed |
| US-7550603-B2 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBOTT LABORATORIES INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7342016-B2 | Farnesyl protein transferase inhibitors as antitumor agents | SCHERING CORPORATION (US) | 2008-03-11 | — | — | US | disclosed |
| EP-1869011-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006110816-A2 | 1H-BENZIMIDAZOLE-4-CARBOXAMIDES SUBSTITUTED WITH A QUATERNARY CARBON AT THE 2-POSITION ARE POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2006-10-19 | — | — | WO | disclosed |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | ABBVIE INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556887-B2 | Processes for the preparation of Veliparib and intermediates thereof | PARP1, PARP3, PARP11 | MEN1 504/4885KMT2A 1612/4885NPSR1 3172/4885 |
| US-20140213610-A1 | PYRAZOLOQUINOLONES ARE POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | MEN1 2568/4885KMT2A 1983/4885NPSR1 4449/4885 |
| US-20200172514-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | PARP1, PARP3, PARP11 | MEN1 504/4885KMT2A 1612/4885NPSR1 3172/4885 |
| US-20060229289-A1 | 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors | PARP1, PARP2, PARP4 | MEN1 3097/4885KMT2A 595/4885NPSR1 4421/4885 |
| US-20190119257-A1 | Processes for the Preparation of Veliparib and Intermediates Thereof | PARP1, PARP3, PARP11 | MEN1 504/4885KMT2A 1612/4885NPSR1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.